The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Danek, A.
Right arrow Articles by George, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danek, A.
Right arrow Articles by George, J. M.

The Journal of Immunology, Vol 131, Issue 3 1173-1177, Copyright © 1983 by American Association of Immunologists

ARTICLES

Specific binding sites for vasoactive intestinal polypeptide on nonadherent peripheral blood lymphocytes

A Danek, MS O'Dorisio, TM O'Dorisio and JM George

Vasoactive intestinal polypeptide (VIP), an octacosapeptide isolated from porcine duodenum and thought to have neuromodulator function in several functional systems (gastrointestinal tract, brain, lung, genital tract, heart), was recently detected in human neutrophils by radioimmunoassay. Subsequent studies demonstrated a VIP-mediated increase in lymphocyte adenylate cyclase. In this paper, VIP binding studies are presented using viable nonadherent human lymphocytes. Binding of 125I-VIP to nylon wool column-purified lymphocytes is specific, time dependent, rapid, and reversible. Bound radioactivity varies linearly with the number of cells used and is displaceable by non-iodinated VIP in a dose-dependent manner with complete displacement between 1 pM and 50 nM. Scatchard analysis of competition experiments demonstrates one class of specific binding sites with a KD of 0.47 +/- 0.23 nM and a Bmax of 24.9 +/- 7.0 pM. This Bmax represents 1700 binding sites/cell. secretin, gastric inhibitory polypeptide, and glucagon did not effectively compete with 125I-VIP for binding sites. This is the first demonstration of VIP receptors in a purified population of human lymphocytes; the data suggest that VIP may modulate lymphocyte function.


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
M. Delgado, D. Pozo, and D. Ganea
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Summers, M. S. O'Dorisio, M. O. Cox, M. Lara-Marquez, and E. J. Goetzl
A Lymphocyte-Generated Fragment of Vasoactive Intestinal Peptide with VPAC1 Agonist Activity and VPAC2 Antagonist Effects
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 638 - 645.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Dorsam and E. J. Goetzl
Vasoactive Intestinal Peptide Receptor-1 (VPAC-1) Is a Novel Gene Target of the Hemolymphopoietic Transcription Factor Ikaros
J. Biol. Chem., April 12, 2002; 277(16): 13488 - 13493.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Delgado, C. Martinez, D. Pozo, J. R. Calvo, J. Leceta, D. Ganea, and R. P. Gomariz
Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-{alpha} and IL-6
J. Immunol., January 15, 1999; 162(2): 1200 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. Ruff and C. Pert
Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin
Science, September 7, 1984; 225(4666): 1034 - 1036.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.